Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus

被引:31
作者
Akhisaroglu, M [1 ]
Manev, R [1 ]
Akhisaroglu, E [1 ]
Uz, T [1 ]
Manev, H [1 ]
机构
[1] Univ Illinois, Dept Psychiat, Inst Psychiat, Chicago, IL 60612 USA
关键词
aging; Alzheimer; antidepressant; fluoxetine; hippocampus; mouse; neurotrophic; S100b; serotonin;
D O I
10.1097/00001756-200308060-00013
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
S100B is a cytokine with neurotophic and neurite-extending activity that has been implicated in the mechanism of action of antidepressants and in the pathobiology of aging associated disorders such as Alzheimer's disease. The antidepressant fluoxetine increases hippocampal S100B content in young adult rats. In humans, brain levels of S100B mRNA and protein increase with advancing age. We assayed hippocampal S100B protein content in young (2 month) and old (24 month) mice, and in old mice treated for 2 weeks with fluoxetine. Using quantitative Western immunoblotting and an immunoassay kit we found higher S100B content in the hippocampus of old mice. Fluoxetine treatment of old mice further increased hippocampal S100B, suggesting that aging does not interfere with fluoxetine's action on hippocampal S100B.
引用
收藏
页码:1471 / 1473
页数:3
相关论文
共 25 条
  • [1] S-100β protects cultured neurons against glutamate- and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT1A-receptor agonist, Bay x 3702
    Ahlemeyer, B
    Beier, H
    Semkova, I
    Schaper, C
    Krieglstein, J
    [J]. BRAIN RESEARCH, 2000, 858 (01) : 121 - 128
  • [2] S100-BETA PROTECTS HIPPOCAMPAL-NEURONS FROM DAMAGE-INDUCED BY GLUCOSE DEPRIVATION
    BARGER, SW
    VANELDIK, LJ
    MATTSON, MP
    [J]. BRAIN RESEARCH, 1995, 677 (01) : 167 - 170
  • [3] S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles
    Donato, R
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2001, 33 (07) : 637 - 668
  • [4] Life-long overexpression of S100β in Down's syndrome:: Implications for Alzheimer pathogenesis
    Griffin, WST
    Sheng, JG
    McKenzie, JE
    Royston, MC
    Gentleman, SM
    Brumback, RA
    Cork, LC
    Del Bigio, MR
    Roberts, GW
    Mrak, RE
    [J]. NEUROBIOLOGY OF AGING, 1998, 19 (05) : 401 - 405
  • [5] HIPPOCAMPAL SEROTONIN LEVELS INFLUENCE THE EXPRESSION OF S100-BETA DETECTED BY IMMUNOCYTOCHEMISTRY
    HARING, JH
    HAGAN, A
    OLSON, J
    RODGERS, B
    [J]. BRAIN RESEARCH, 1993, 631 (01) : 119 - 123
  • [6] Ca2+-binding S100 proteins in the central nervous system
    Heizmann, CW
    [J]. NEUROCHEMICAL RESEARCH, 1999, 24 (09) : 1097 - 1100
  • [7] Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation
    Huttunen, HJ
    Kuja-Panula, J
    Sorci, G
    Agneletti, AL
    Donato, R
    Rauvala, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (51) : 40096 - 40105
  • [8] Serum S-100β as a possible marker of blood-brain barrier disruption
    Kapural, M
    Krizanac-Bengez, L
    Barnett, G
    Perl, J
    Masaryk, T
    Apollo, D
    Rasmussen, P
    Mayberg, MR
    Janigro, D
    [J]. BRAIN RESEARCH, 2002, 940 (1-2) : 102 - 104
  • [9] SELECTIVE INCREASE IN S-100-BETA-PROTEIN BY AGING IN RAT CEREBRAL-CORTEX
    KATO, K
    SUZUKI, F
    MORISHITA, R
    ASANO, T
    SATO, T
    [J]. JOURNAL OF NEUROCHEMISTRY, 1990, 54 (04) : 1269 - 1274
  • [10] New antidepressant drugs that do not cross the blood-brain barrier
    Manev, H
    Manev, R
    [J]. MEDICAL HYPOTHESES, 2002, 58 (01) : 83 - 84